Psoriatic Arthritis Research Review, Issue 4

In this issue:

Final safety and efficacy data for tofacitinib from OPAL Balance
Enthesitis predicts worse disease activity
DISCOVER-2 demonstrates one-year efficacy for guselkumab in biologic-naïve patients
Axial disease is common in PsA
Onycholysis may be a marker for subclinical distal enthesopathy and bone erosions in the absence of PsA
Real-world effectiveness of golimumab in PsA, AS and RA
IL-12/23is demonstrate longer duration of persistence than TNFis or tsDMARDs
Female patients have a significantly greater disease burden with greater pain and impairment
Psoriatic manifestations increase disease burden in SpA
Is fatigue in PsA related to disease activity?

Please login below to download this issue (PDF)

Subscribe